Pharmaceuticals & Biotech Taiwanese Community

Lotus Pharmaceutical is pushing harder into Southeast Asia through acquisitions and partnerships, while bringing more production in-house to lift profitability. The big question is whether new drug launches and deal integration can deliver the growth story without getting tripped up by delays, currency swings, or heavy spending on research.Read more

Bora Pharmaceuticals is leaning harder into contract drug manufacturing and rare‑disease medicines, aiming to move away from lower‑profit generic drugs and build a steadier, higher‑quality business. The big question is whether new capacity, recent deal-making, and a growing project pipeline can turn into dependable sales—before pricing pressure and U.S. policy uncertainty slow things down.Read more

Bora Pharmaceuticals is riding a push to make more medicines closer to home, but it’s also building new capacity that could take time to fill. The big question is whether its move toward higher-value neurology and complex medicines can lift profits fast enough before competition, execution hiccups, or shifting policy winds get in the way.Read more

Bora Pharmaceuticals is bouncing back from recent production setbacks and is leaning hard into making higher-value medicines, with a big push to expand its contract manufacturing footprint in the US. The upside comes from winning more large pharma clients and building longer-term, repeat business, but the story depends on executing major facility expansions and keeping a few key customers.Read more

Lotus Pharmaceutical is pushing into Southeast Asia and higher-complexity generic medicines, which could open new growth paths as global demand for affordable drugs rises. But heavier regulation, trade barriers, and reliance on a handful of key products in the U.S. could squeeze profits and make results bumpier than investors expect.Read more

Lotus Pharmaceutical is turning recent deal integrations into fast growth across Southeast Asia, while using its own manufacturing and new product launches to lift profitability. The big question is whether that momentum can outlast rising competition, higher research spending, and heavy dependence on a small number of cancer medicines.Read more